Related Experiment Videos
Plafibride treatment and serum lipids in hyperlipoproteinemias
F Rodriguez1, I M López, E Jover
1Medical Faculty of Valladolid, Spain.
Insights
Plafibride treatment significantly improved lipid profiles in patients with primary hyperlipoproteinemia, reducing cholesterol and triglycerides while increasing HDL cholesterol. The drug demonstrated good tolerance and no adverse effects on serum enzymes over two years.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Primary hyperlipoproteinemia encompasses various genetic disorders affecting lipid metabolism.
- Familial hypercholesterolemia (phenotype IIa), familial combined hyperlipidemia (phenotype IIb), and familial hypertriglyceridemia (phenotype IV) are distinct subtypes.
- Effective management strategies are crucial for preventing cardiovascular complications.
Purpose of the Study:
- To evaluate the efficacy and safety of Plafibride in treating primary hyperlipoproteinemia phenotypes.
- To assess the impact of Plafibride on key lipid and metabolic parameters.
- To determine the long-term tolerability and potential side effects of Plafibride.
Main Methods:
- A two-year prospective study involving 26 patients with primary hyperlipoproteinemia (phenotypes IIa, IIb, IV).
- Patients followed a standardized diet (45% carbohydrates, 33% fats, 22% protein).
- Plafibride administered at 400 mg three times daily (TID) post-meal; biochemical markers monitored.
Main Results:
- Significant reductions observed in cholesterol, triglycerides, glucose, insulin, and lecithin levels.
- Significant increases noted in HDL cholesterol and free fatty acids.
- Plafibride showed good patient tolerance with no adverse effects on serum enzymes.
Conclusions:
- Plafibride effectively improves lipid profiles and metabolic parameters in patients with primary hyperlipoproteinemia.
- The drug is well-tolerated and safe for long-term use in these patient populations.
- Plafibride represents a viable therapeutic option for managing hyperlipoproteinemia phenotypes.
Abstract:
A study was made of 26 patients suffering from primary hyperlipoproteinemia; 8 belonging to familial hypercholesterolemia (phenotype IIa), 9 to familial combined hyperlipidemia (phenotype IIb, 9 to familial hypertriglyceridemia (phenotype IV). During treatment, which was continued for two years, all patients received a diet consisting of 45% carbohydrates, 33% fats and 22% protein. They were given 400 mg (TID) of Plafibride after breakfast, lunch and dinner. In the three phenotypes studied, significant decreases in cholesterol, triglycerides, glucose, insulin and lecithin were observed, while there was an increase in HDL cholesterol, free fatty acids and lysolecithin. Tolerance to the drug was good, and a study of different serum enzymes revealed no undesirable collateral effects.